Ronald Fink

Deputy Managing Editor. An award-winning financial writer and editor with more than two decades of experience, Ron has served on staff at The Wall Street Journal, Institutional Investor, Crain's Financial Week, CFO Magazine, U.S. Banker, Financial World, and Medical Economics, and has contributed to such publications as Global Finance, Crain's New York Business, Reuters, the ETF Report, and the University of Chicago's Capital Ideas. Ron has also published fiction in a number of literary magazines. He resides in Brooklyn, NY.

Recent Articles By The Author

Why Hudson's Bay Just Unloaded a Massive Lord & Taylor Store for $850 Million

Why Hudson's Bay Just Unloaded a Massive Lord & Taylor Store for $850 Million

The Canadian retailer under pressure from an insurgent sells Lord & Taylor's Fifth Avenue flagship as part of a strategic partnership with WeWork.

Boards May Be Right to Resist Activists: Trump's Latest SEC Pick

Boards May Be Right to Resist Activists: Trump's Latest SEC Pick

Support for shareholder activism by President Trump's latest pick for the SEC was in ample evidence in a recent interview he gave to The Deal. But Robert Jackson Jr. defended the right of boards to resist activists' proposals that other shareholders dislike.

The World Seems Bizarre

The World Seems Bizarre

And it isn't limited to U.S. politics.

Mylan Just Can't Catch a Break

Mylan Just Can't Catch a Break

Monday was a wild start to the week.

Trump, General Electric and Tesla What a Crazy Week: The BIG Deal

Trump, General Electric and Tesla What a Crazy Week: The BIG Deal

Here is something to chat about this weekend.

Deere's Massive $5.2 Billion Deal for a German Company May Signal Something Surprising: The BIG Deal

Deere's Massive $5.2 Billion Deal for a German Company May Signal Something Surprising: The BIG Deal

Here's what's hot on Deere's latest acquisition.

Deals of the Week: Waiting for Clarity

Deals of the Week: Waiting for Clarity

The week's action suggests other dealmakers may be thinking the same thing as Pfizer CEO Ian Read.